First human trial for new mono and Cancer-Linked virus vaccines
NCT ID NCT06908096
Summary
This early-stage study is testing the safety of two new experimental vaccines designed to prevent infection with Epstein-Barr virus (EBV), which causes mono and is linked to certain cancers and autoimmune diseases. The trial will enroll 750 healthy adults aged 18-29, including both people who have never had EBV and those who have. Participants will receive three injections over several months and be monitored for side effects and immune responses for about 17 months.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for EBV are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
National Institutes of Health Clinical Center
RECRUITINGBethesda, Maryland, 20892, United States
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.